79 related articles for article (PubMed ID: 11422740)
21. Effects of vitamin D on kidney histology and trpv1 channels in doxorubicin-induced nephropathy.
Gurel A; Atli H; Kaya N; Onalan E; Kuloglu T; Aygen B
Int J Clin Exp Med; 2015; 8(8):13548-55. PubMed ID: 26550293
[TBL] [Abstract][Full Text] [Related]
22. Role of Paricalcitol in Modulating the Immune Response in Patients with Renal Disease.
Lucisano S; Arena A; Stassi G; Iannello D; Montalto G; Romeo A; Costantino G; Lupica R; Cernaro V; Santoro D; Buemi M
Int J Endocrinol; 2015; 2015():765364. PubMed ID: 26451144
[TBL] [Abstract][Full Text] [Related]
23. Paricalcitol Inhibits Aldosterone-Induced Proinflammatory Factors by Modulating Epidermal Growth Factor Receptor Pathway in Cultured Tubular Epithelial Cells.
Morgado-Pascual JL; Rayego-Mateos S; Valdivielso JM; Ortiz A; Egido J; Ruiz-Ortega M
Biomed Res Int; 2015; 2015():783538. PubMed ID: 26064952
[TBL] [Abstract][Full Text] [Related]
24. Calcitriol ameliorates renal damage in a pre-established proteinuria model.
Maquigussa E; Arnoni CP; Pereira LG; Boim MA
Mol Med Rep; 2015 Jul; 12(1):1009-15. PubMed ID: 25823676
[TBL] [Abstract][Full Text] [Related]
25. Differential expression and regulation of Klotho by paricalcitol in the kidney, parathyroid, and aorta of uremic rats.
Ritter CS; Zhang S; Delmez J; Finch JL; Slatopolsky E
Kidney Int; 2015 Jun; 87(6):1141-52. PubMed ID: 25692955
[TBL] [Abstract][Full Text] [Related]
26. Cardiac and renal effects of atrasentan in combination with enalapril and paricalcitol in uremic rats.
Ritter C; Zhang S; Finch JL; Liapis H; Suarez E; Ferder L; Delmez J; Slatopolsky E
Kidney Blood Press Res; 2014; 39(4):340-52. PubMed ID: 25300759
[TBL] [Abstract][Full Text] [Related]
27. Serum fibroblast growth factor-23 is associated with incident kidney disease.
Rebholz CM; Grams ME; Coresh J; Selvin E; Inker LA; Levey AS; Kimmel PL; Vasan RS; Eckfeldt JH; Feldman HI; Hsu CY; Lutsey PL;
J Am Soc Nephrol; 2015 Jan; 26(1):192-200. PubMed ID: 25060052
[TBL] [Abstract][Full Text] [Related]
28. Vitamin D and chronic kidney disease.
Kim CS; Kim SW
Korean J Intern Med; 2014 Jul; 29(4):416-27. PubMed ID: 25045287
[TBL] [Abstract][Full Text] [Related]
29. Pathogenesis and novel treatment from the mouse model of type 2 diabetic nephropathy.
Furukawa M; Gohda T; Tanimoto M; Tomino Y
ScientificWorldJournal; 2013; 2013():928197. PubMed ID: 23737732
[TBL] [Abstract][Full Text] [Related]
30. Lessons From the KK-Ay Mouse, a Spontaneous Animal Model for the Treatment of Human Type 2 Diabetic Nephropathy.
Tomino Y
Nephrourol Mon; 2012; 4(3):524-9. PubMed ID: 23573479
[TBL] [Abstract][Full Text] [Related]
31. Vitamin D status and outcomes after renal transplantation.
Bienaimé F; Girard D; Anglicheau D; Canaud G; Souberbielle JC; Kreis H; Noël LH; Friedlander G; Elie C; Legendre C; Prié D
J Am Soc Nephrol; 2013 Apr; 24(5):831-41. PubMed ID: 23539758
[TBL] [Abstract][Full Text] [Related]
32. Nuclear hormone receptors in podocytes.
Khurana S; Bruggeman LA; Kao HY
Cell Biosci; 2012 Sep; 2(1):33. PubMed ID: 22995171
[TBL] [Abstract][Full Text] [Related]
33. Effect of vitamin-D analogue on albuminuria in patients with non-dialysed chronic kidney disease stage 4-5: a retrospective single center study.
Jørgensen HS; Winther S; Povlsen JV; Ivarsen P
BMC Nephrol; 2012 Sep; 13():102. PubMed ID: 22958603
[TBL] [Abstract][Full Text] [Related]
34. Effects of 1,25-(OH)(2)D (3) on the expressions of vitamin D receptor, STAT5 and cytoskeletal rearrangement in human monocytes incubated with sera from type 2 diabetes patients and diabetic nephropathy patients with uremia.
Yang M; Shen Z; Chen D; Gan H; Shen Q; Yang B; Du X
Inflamm Res; 2012 May; 61(5):511-20. PubMed ID: 22322482
[TBL] [Abstract][Full Text] [Related]
35. Vitamin D therapy in chronic kidney disease and end stage renal disease.
Melamed ML; Thadhani RI
Clin J Am Soc Nephrol; 2012 Feb; 7(2):358-65. PubMed ID: 22193236
[TBL] [Abstract][Full Text] [Related]
36. Nuclear receptors in renal disease.
Levi M
Biochim Biophys Acta; 2011 Aug; 1812(8):1061-7. PubMed ID: 21511032
[TBL] [Abstract][Full Text] [Related]
37. Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism.
Wang XX; Jiang T; Shen Y; Santamaria H; Solis N; Arbeeny C; Levi M
Am J Physiol Renal Physiol; 2011 Mar; 300(3):F801-10. PubMed ID: 21209008
[TBL] [Abstract][Full Text] [Related]
38. 1, 25-dihydroxyvitamin D3 decreases adriamycin-induced podocyte apoptosis and loss.
Zou MS; Yu J; Nie GM; He WS; Luo LM; Xu HT
Int J Med Sci; 2010 Aug; 7(5):290-9. PubMed ID: 20827429
[TBL] [Abstract][Full Text] [Related]
39. Neutrophil responses to injury or inflammation impair peripheral gustatory function.
Steen PW; Shi L; He L; McCluskey LP
Neuroscience; 2010 May; 167(3):894-908. PubMed ID: 20219636
[TBL] [Abstract][Full Text] [Related]
40. Emerging risk factors and markers of chronic kidney disease progression.
Kronenberg F
Nat Rev Nephrol; 2009 Dec; 5(12):677-89. PubMed ID: 19935815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
